SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-062628
Filing Date
2023-08-02
Accepted
2023-08-02 17:00:18
Documents
15
Period of Report
2023-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea182689-8k_abvcbio.htm   iXBRL 8-K 27098
2 TERM SHEET DATED JULY 31, 2023 ea182689ex10-1_abvcbio.htm EX-10.1 78067
3 PRESS RELEASE DATED AUGUST 1, 2023 ea182689ex99-1_abvcbio.htm EX-99.1 12075
4 GRAPHIC ex99-1_001.jpg GRAPHIC 2352
  Complete submission text file 0001213900-23-062628.txt   315948

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE abvc-20230802.xsd EX-101.SCH 3021
6 XBRL LABEL FILE abvc-20230802_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE abvc-20230802_pre.xml EX-101.PRE 22363
9 EXTRACTED XBRL INSTANCE DOCUMENT ea182689-8k_abvcbio_htm.xml XML 3216
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 231136711
SIC: 2834 Pharmaceutical Preparations